Metabolic | Boehringer Ingelheim

Boehringer Ingelheim

For Healthcare Professionals

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Area
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Area

Section Overview

Cardiovascular

Metabolic

Inflammation

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact
Logout

Boehringer Ingelheim

Metabolic

Iinagliptin

Format

Sort by

Reset all filters

EMPA-KIDNEY trial results

7:07

EMPA-KIDNEY trial results

Watch now Opens in new tab

Time Travel in CRM Travelogue: “The Butterfly Effect”

1:06:17

Time Travel in CRM Travelogue: “The Butterfly Effect”

Watch now Opens in new tab

EMPA-KIDNEY’s broad CKD population: potential mechanisms

1:14

EMPA-KIDNEY’s broad CKD population: potential mechanisms

Watch now Opens in new tab

SGLT2i benefits from a CRM perspective

1:37

SGLT2i benefits from a CRM perspective

Watch now Opens in new tab

Empagliflozin in the Midst of CKD trials

1:54

Empagliflozin in the Midst of CKD trials

Watch now Opens in new tab

JRDHF||How effective is Empagliflozin with or without ARNI?

1:11

JRDHF||How effective is Empagliflozin with or without ARNI?

Watch now Opens in new tab

Pagination

Load More

Home
All our resources for healthcare profess...
Metabolic

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI logo

Privacy
Terms of use
Sitemap
Contact

Copyright © 2025 Boehringer Ingelheim (Philippines), Inc. All rights reserved. Use of this Site is subject to the Terms of Use and Privacy Statement. Prepared June 2025